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Abstract: Sex development is a very complex biological event that requires the concerted collaboration
of a large network of genes in a spatial and temporal correct fashion. In the past, much has been
learned about human sex development from monogenic disorders/differences of sex development
(DSD), but the broad spectrum of phenotypes in numerous DSD individuals remains a conundrum.
Currently, the genetic cause of less than 50% of DSD individuals has been solved and oligogenic
disease has been proposed. In recent years, multiple genetic hits have been found in individuals with
DSD thanks to high throughput sequencing. Our group has been searching for additional genetic
hits explaining the phenotypic variability over the past years in two cohorts of patients: 46,XY DSD
patients carriers of NR5A1 variants and 46,XY DSD and 46,XX DSD with MAMLD1 variants. In both
cohorts, our results suggest that the broad phenotypes may be explained by oligogenic origin, in
which multiple hits may contribute to a DSD phenotype, unique to each individual. A search for an
underlying network of the identified genes also revealed that a considerable number of these genes
showed interactions, suggesting that genetic variations in these genes may affect sex development
in concert.
Keywords: differences of sex development; DSD; oligogenicity; oligogenic disease; 46,XY DSD; 46,XX
DSD; hypospadias; high throughput sequencing techniques; HTS
1. Introduction
Sex development is a very complex biological event that requires the concerted collaboration of
a large network of genes in a spatial and temporal correct fashion [1]. In the past, much has been
learned about human sex development from monogenic disorders/differences of sex development
(DSD), but the broad spectrum of phenotypes in numerous DSD individuals remains a conundrum.
Currently, the genetic cause of less than 50% of DSD individuals has been solved [2,3]. Oligogenic
disease has been proposed. In fact, multiple genetic hits, which might not be deleterious by themselves,
have been found in individuals with DSD [4–14].
Oligogenic inheritance is also currently discovered for several other disorders of the endocrine
systems. For instance, in congenital hypogonadotropic hypogonadism (CHH) more than 25 causative
genes are now considered to explain around 50% of the cases, and in at least 20% of cases
disease-causing variants in two or more genes have been identified [15–21]. Similarly, in congenital
hypothyroidism digenic [22,23] and polygenic [24] candidate-gene variants have been associated with
the phenotypes [25].
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2. Monogenic Inheritance in Humans with DSD
In humans, the DSD phenotypes manifesting discordances among sex chromosomes, gonadal
and/or genital development are classified into three groups, namely sex chromosome DSD, 46,XX
DSD or 46,XY DSD [26]. Additionally, for each of the 46,XX and 46,XY DSD groups, multiple gene
and corresponding protein defects have been characterized. Animal models with the corresponding
gene defects have generally been able to reproduce the human phenotype. Monogenic causes for
both 46,XX and 46,XY DSD include genes regulating gonadal development, gonadal and/or adrenal
steroidogenesis, genital ducts’ development, and target-cell responsiveness [2,3,27,28]. Clinical and
biochemical phenotypes of DSD due to genetic defects, causing (a) a complete loss of protein function
resulting in complete gonadal dysgenesis (CGD), (b) classical forms of defects of steroidogenesis (both
gonadal and/or adrenal), and (c) hormone resistance, mostly relate directly to the underlying genetic
defect, which is then typically monogenetic. Whenever possible, genetic family studies will confirm
this type of inheritance.
Defects in genes regulating gonadal development and causing gonadal dysgenesis, either complete
or partial, or gonadal sex reversal include a large groups of genes in 46,XY DSD (e.g., ARX, ATRX,
CBX2, DAX1, DHH, DMRT1, EMX2, ESR2, FGFR2, GATA4, HHAT, MAP3K1, NR5A1, SOX9, SRY,
TSPYL1, WNT4, WT1, ZFPM2, and ZNRF3) as well as in 46,XX DSD (e.g., BMP15, FGF9, FOXL2, NR2F2,
NR5A1, NUP107, RSPO1, SOX3, SOX9, SOX10, SRY, and WNT4) [3,28]. Gene defects of steroidogenesis
causing DSD include AKR1C2, AKR1C4, CYB5A, CYP11A1, CYP11B1, CYP17A1, CYP19A1, CYP21A2,
DHCR7, HSD3B2, HSD17B3, POR, SRD5A2, and STAR [3,28]. Gene defects affecting gonadal ducts’
development comprise AMH in 46,XY and HOXA13 in 46,XX DSD [3,28]. Finally, hormone resistance
syndromes causing monogenic forms of DSD are due to defects in genes AMHR, AR, ESR1, and
LHCGR [3,28].
3. Digenic and Combined DSDs Described by Karyotyping and Single Candidate Gene Analyses
Patients carrying a digenic or combined DSD disease have been described even before the era of
high throughput sequencing (HTS), when either the phenotype suggested the involvement of more
than one gene defect or, incidentally, when an abnormal sex-chromosome karyotype is combined with
an another gene defect [29–35].
Androgen receptor gene (AR) defects have occasionally been described in patients with a complete
or partial androgen insensitivity syndrome (CAIS or PAIS) in whom sex chromosome analysis revealed
a 47,XXY karyotype corresponding to a Klinefelter syndrome [29–32]. Similarly, a patient with a clinical
and molecular diagnosis of familial male-limited precocious puberty due to an activating LHCGR
mutation was demonstrated to have a 47,XXY karyotype upon detection of abnormally increased
gonadotropin levels [33].
A 46,XY female DSD patient has been reported to combine AR and POR gene mutations causing a
PAIS phenotype at birth, while clinical and biochemical phenotype at adrenarche suggested typical
steroid anomalies of POR deficiency [34].
An adult 46,XY female DSD patient with primary amenorrhea, gonadal dysgenesis, bilateral
gonadoblastoma, and dysgerminoma was first found to carry a missense SRY mutation, but later
developed progressive focal segmental glomerular sclerosis and kidney failure. WT1 gene analysis
revealed an intron 9 splice-site mutation and confirmed Frasier syndrome [35].
4. Oligogenic DSDs Described by High Throughput Sequencing (HTS)
In the past decade, high throughput sequencing (HTS) has changed the genetic approach in
research and diagnostics. Whole-exome sequencing (WES) has led to the discovery of many new genes
and has given insight into complex traits [36–38]. In addition, the HTS approach is discovering that
some patients carry variants in more than one gene that may contribute to their phenotype.
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Oligogenic DSD origin has been revealed either as a result of HTS directly or in a second approach,
when the first candidate gene detected seemed not sufficient to explain the phenotype. Several recent
studies demonstrate that many patients carry a gene variant likely responsible for the phenotype
together with other variants in known or new candidate genes for DSD [4–14].
4.1. Digenic and Oligogenic Origin of DSD Revealed by HTS
In sex development, digenic inheritance has recently been suggested by WES analysis in a 46,XY
DSD patient with gonadal dysgenesis (NR5A1 and MAP3K1 variants) [7] and in a family with a 46,XY
DSD male (NR5A1 variant) and 46,XY DSD female (NR5A1 and TBX2 variants) [8] (Table 1).
In 46,XY patients with hypospadias, an oligogenic origin was also suggested by several HTS
studies [4,5,9–12,14] (Table 1).
Kon et al. [4] analyzed 25 causative-candidate-susceptibility genes in 62 46,XY patients with
non-syndromic and non-familial hypospadias. Causative mutations were described in seven patients
(11.3%), with the AR gene accounting for the highest proportion (4/7) followed by SRD5A2, HSD3B2,
and BCN2. In addition, four of these patients carried additional variants in other genes: one hemizygous
AR patient carried heterozygous missense substitutions in HOXB6 and MAMLD1 and one patient with
a homozygous missense mutation in HSD3B2 had an additional heterozygous missense variant in
SRD5A2 that is reported to retain 3% of enzyme activity. The authors concluded that non-syndromic
hypospadias may result from a digenic mechanism (Table 1).
Results from an analysis using a targeted DSD gene panel (including 64 known DSD and 967
candidate genes) described a total of 13 46,XY DSD patients who had more than one curated variant in
diagnostic DSD genes [5]. Eight of these patients were classified as 46,XY DSD of unknown origin and
five had hypospadias. Of the eight patients with 46,XY DSD of unknown origin, five had a known
variant in the AR in combination with other DSD gene variants. Two patients had an additional
pathogenic homozygous variant in SRD5A2 or HSD17B3, respectively, with the patient combining
AR and HSD17B3 presenting a third variant in SOX9. Two other AR variant carriers had additional
variants in a testis development gene, WDR11 and ZFPM2, the other one carried variants in NR5A1 and
FGFR2. Three individuals had a pathogenic variant in a testis development gene (MAP3K1 or NR5A1)
in combination with a less damaging DSD gene variant in WT1, LHCGR, or ZFPM2. Of the five patients
with hypospadias, three were found to have a likely pathogenic variant in a testis development gene
(MAP3K1 or ZFPM2) in combination with a variant of unknown significance (VUS) in an additional
DSD gene (WDR11, MAP3K1, or GATA4), while one patient had two homozygous pathogenic variants
(in HSD3B2 and in a CHH gene, GNRHR) and the last patient carried variants of unknown significance
(VUS) in two genes of gonadal development (CHD7 and DHH) (Table 1).
In most cases with oligogenic inheritance, at least two of the genes were predicted to be pathogenic
and/or contribute to the phenotype. Robevska et al. [9] analyzed the functional characteristics of
NR5A1 gene variants and the phenotypes from 15 patients (most of them described in the study of
Eggers et al. [5]). Two of these patients carried each an additional heterozygous variant in known 46,XY
DSD genes, ZFPM2 [5] and SRD5A2. Whether these additional gene variants are able to modulate the
NR5A1 patient phenotypes has been suggested by the authors. The patient carrying an additional
ZFPM2 variant presented a more severe phenotype than another patient with the same NR5A1 variant
(p.Arg84His) only; the heterozygous SRD5A2 variant (p.Arg227Gln) has been described in numerous
patients with biallelic SRD5A2 mutations, but also as a monoallelic finding in patients with micropenis
and/or hypospadias [9] (Table 1).
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Table 1. Oligogenic disorders/differences of sex development (DSDs) described by high throughput sequencing (HTS) techniques.
First Gene Other Genes Zygosity Variant Classification Patient’s Phenotype References Method
NR5A1 MAP3K1 het/het LP*/B 46,XY DSD GD Mazen et al., 2016 [7] WES
NR5A1 TBX2 het/het P/P 46,XY DSD complete GD Werner et al., 2017 [8] WES
AR HOXB6, MAMLD1 hemi/het/hemi P/P/LB* 46,XY DSD Kon et al., 2015 [4] Gene panel
HSD3B2 SRD5A2 homo/het P/P 46,XY DSD Kon et al., 2015 [4] Gene panel
AR SRD5A2 hemi/homo P/P 46,XY DSD Eggers et al., 2016 [5] Gene panel
AR HSD17B3, SOX9 hemi/homo/het P/P/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
AR NR5A1, FGFR2 hemi/het/het P/LP/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
AR ZFPM2 hemi/het LP/P 46,XY DSD Eggers et al., 2016 [5] Gene panel
AR WDR11 hemi/het P/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
MAP3K1 WT1 het/het LP/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
MAP3K1 WDR11 het/het LP/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
MAP3K1 LHCGR het/homo VUS/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
ZFPM2 MAP3K1 2xhet/het LP/LP/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
NR5A1 ZFPM2 het/het P/VUS 46,XY DSD Eggers et al., 2016 [5]; Robevska et al., 2018 [9] Gene panel
ZFPM2 GATA4 het/het LP/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
HSD3B2 GNRHR homo/homo P/P 46,XY DSD Eggers et al., 2016 [5] Gene panel
CHD7 DHH het/het VUS/VUS 46,XY DSD Eggers et al., 2016 [5] Gene panel
NR5A1 SRD5A2 het/het P/P 46,XY DSD Robevska et al., 2018 [9] Gene panel
AR SOX9, POR hemi/het/het P/VUS/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
AR CBX2 hemi/het VUS/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
AR DMRT1 hemi/het VUS/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
AR POR hemi/het P/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
AR DHCR7 hemi/het P/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
HSD17B3 CYP17A1 comp het/het P/P/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
HOXA13 ARX het/hemi LP/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
AKR1C4 AMH het/het VUS/VUS 46,XY DSD Kolesinska et al., 2018 [10] Gene panel
GATA4 LHCGR het/het VUS*/P 46,XY DSD Martinez de LaPiscina et al., 2018 [11] Gene panel
GATA4 LRP4 het/het VUS*/VUS 46,XY DSD Martinez de LaPiscina et al., 2018 [11] Gene panel
NR5A1 SRY, FGF10 hemi/het P/LP/VUS* 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 CST9 het/het LP/VUS* 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 CST9 het/het LP/LP* 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 AR, MYH6 het/hemi/het LP/LP/VUS 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 EGF het/het LP/VUS 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 BMP2 het/het LP/LB 46,XY DSD Wang H et al., 2018 [12] Gene panel
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Table 1. Cont.
First Gene Other Genes Zygosity Variant Classification Patient’s Phenotype References Method
NR5A1 SOX3 het/hemi LP/LP 46,XY DSD Wang H et al., 2018 [12] Gene panel
NR5A1 HSD17B3, WT1 het/het/het LP/VUS*/LP 46,XY DSD Wang H et al., 2018 [12] Gene panel
SRD5A2 PROKR2 comp het/het LP/P/LP 46,XY DSD Zhang W et al., 2019 [14] Gene panel
AR PROKR2 hemi/het LP/LP 46,XY DSD Zhang W et al., 2019 [14] Gene panel
AR TRIM17 hemi/het LP/LP 46,XY DSD Zhang W et al., 2019 [14] Gene panel
NR5A1 INHA het/het P*/VUS* 46,XY DSD Camats et al., 2018 [13] WES
NR5A1 AKR1C3, DOCK8, FSHR, NCOR1, POR all het, NCOR1: 2xhet P*/VUS*/VUS*/VUS*/VUS*/VUS*/VUS* 46,XY DSD Camats et al., 2018 [13] WES
NR5A1 CACNG4, FBLN2, NAV1, SMAD6, SRA1,ZDHHC11, ZFPM2 all het LP*/VUS*/VUS*/VUS*/LP*/LB*/VUS*/VUS* 46,XY DSD Camats et al., 2018 [13] WES
NR5A1 CHD7, DENND1A, GDNF, GLI2, SOX30 all het P*/VUS*/VUS*/LB*/B*/VUS* 46,XY DSD Camats et al., 2018 [13] WES
MAMLD1 CYP1A1, EVC, GRID1, NOTCH1, RET, RIPK4,ZBTB16
all het, EVC: 2xhet,
RIPK4: 2xhet B*/VUS/VUS/VUS/VUS/LB/LP/VUS/VUS/VUS 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1 RECQL4 het/het B*/VUS 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1 GLI2, RECQL4 het/het/het LB*/VUS/LB 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1 CDH23, COL9A3, MAML1, NOTCH1 all het LB*/P/VUS/VUS/LB 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1 BNC2, FGF10, HSD3B2, IRX5, MAML2,NOTCH2 all het LB*/VUS/VUS/LP/VUS/VUS/VUS 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1
ATF3, BNC2, CYP1A1, EYA1, FLNA, FRAS1,
GLI3, HOXA13, IRX5, IRX6, MAML1, MAML3,
NRP1, PROP1, PTPN11, WDR11
all het, FLNA: hemi LB*/VUS/VUS/VUS/VUS/LB/VUS/VUS/VUS/VUS/VUS/VUS/VUS/VUS/VUS/VUS/VUS 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1 EVC, MAML3, NOTCH2, PPARGC1B, WDR11 all het LB*/VUS/VUS/VUS/VUS/VUS 46,XY DSD Flück et al., 2019 [6] WES
MAMLD1
CUL4B, DAPK1, EMX2, FREM2, IGFBP2,
MAML2, MAML3, MYO7A, NOTCH1, PIK3R3,
TGFBI, WNT9A, WNT9B
all het, CUL4B: hemi LB/LB/VUS/VUS/LP/VUS/VUS/VUS/-/LP*/VUS/VUS/VUS/VUS/VUS 46,XX POF Flück et al., 2019 [6] WES
* variant classification revised in varsome/ACMG and HGMD (July 2019). GD: gonadal dysgenesis; homo: homozygous; het: heterozygous; hemi: hemizygous; B: benign; LB: likely
benign; VUS: variant of uncertain significance; LP: likely pathogenic; P: pathogenic; WES: whole-exome sequencing.
Int. J. Mol. Sci. 2020, 21, 1809 6 of 14
Kolesinska et al. [10] analyzed 37 DSD candidate genes and 21 CHH genes in 35 46,XY DSD
patients; eight (23%) were found to carry gene variations in more than one candidate gene. To evaluate
whether the DSD cohort was statistically enriched for oligogenicity, they compared the results to exome
sequencing data from 247 male participants in the ‘Cohorte Lausannoise’ CoLaus control population.
Variants in the 37 DSD-related genes were filtered for non-synonymous variants with a MAF <1.0%,
including nonsense, splice-site (±6 base pairs) and missense variants found to be damaging in at
least one of the two protein prediction programs, SIFT or MutationTaster. They found a statistical
enrichment in oligogenic variants in their DSD cohort compared to CoLaus controls (23% vs. 2.5%;
p = 0.0003). From these eight patients, five combined an AR gene defect with another monoallelic
gene defect in either a gonadal dysgenesis gene (SOX9, CBX2, or DMRT1) or androgen synthesis
gene (POR or DHCR7). Another patient was compound heterozygous for an androgen synthesis
gene (HSD17B3) variant and a heterozygous variant in CYP17A1. Still, another patient combined two
gonadal dysgenesis genes (HOXA13 and ARX), and one patient combined two heterozygous gene
variants in the androgen synthesis gene (AKR1C4) and the genital duct development gene (AMH)
(Table 1).
In a study on GATA4 [11], two 46,XY male DSD patients with cryptorchidism, micropenis, and
hypospadias without cardiac defects were heterozygous for GATA4 missense variants located close to
the GATA4 DNA-binding site, but both variants had wild-type functional activity in vitro. HTS analysis
in these two patients revealed additional gene variants in the genes for LHCGR and LRP4, respectively,
which are likely contributing to the DSD phenotype [11] (Table 1).
Furthermore, analysis of 70 Chinese patients with a 46,XY DSD phenotype (who could not be
diagnosed according to the typical clinical phenotypes and routine candidate gene strategies; most
patients presented with undervirilization, such as microphallus, variable degrees of hypospadias,
and cryptorchidism) with a candidate gene panel (33 candidates and 47 genes involved in sexual
differentiation and development) revealed that 19 out of 33 patients presented multiple (two or more)
gene variants, a proportion significantly higher than the rate observed in 144 individuals from a control
population [12]. The highest frequency of combined variants was detected in the genes for AR, SRD5A2
and NR5A1. Eighty percent (8 of 10) of patients carrying an heterozygous NR5A1 variant presented
additional gene variants in SRY, FGF10, CST9, AR, MYH6, EGF, BMP2, SOX3, HSD17B3, or WT1
(Table 1). The authors concluded that multiple genetic lesions in some cases suggested that DSD is
not a simple monogenic disorder and that a potential digenic or oligogenic pattern may underlie the
pathological process [12].
In a recent study of 130 Han Chinese 46,XY males with hypospadias of variable degrees (associated
or not with other DSD signs and/or other system involvement), 105 genes were analyzed on a panel
including genes involved in gonadal/urogenital development (55 well recognized genes), CHH (seven
genes), syndromic DSD (four genes), and others (39 genes) [14]. Genetic variants were identified in
25 patients (19.21%): 13 (52%) in the SRD5A2 gene (compound heterozygous or homozygous), six
(24%) in the AR gene (hemizygous), and six were heterozygous in other genes. Among them, gene
variants in two different genes were only detected in three patients (12%): one compound heterozygous
for SRD5A2 and one hemizygous for AR carried the same PROKR2 heterozygous mutation (p.W178S,
previously reported in other Chinese patients), while another patient hemizygous for the AR gene
carried a novel heterozygous TRIM17 mutation (Table 1). The authors concluded that polygenic
inheritance in their population may be a rare genetic cause of hypospadias. In fact, this study detected
a high proportion of monogenic 46,XY DSD causes (SRD5A2 and AR genes, with several mutations
previously detected in the Han Chinese population), while no gene variants were detected in other
candidate genes frequently found in other 46,XY DSD series such as NR5A1 and MAMLD1 [5,39,40].
4.2. HTS in a Second Approach to Detect Digenic or Oligogenic Origin of DSD
In 2012, we studied heterozygous NR5A1 gene variants detected in 10 DSD patients (nine 46,XY
DSD and one 46,XX with primary ovarian insufficiency) in whom other DSD-causing genes such as
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AR, SRD5A2, and CYP17A1 were ruled out by Sanger sequencing [39]. While these gene variants were
pathogenic in functional assays when tested alone, they acted similarly to wild-type when tested in
heterozygote state together with the wild-type [39]. Thus, our study, similar to others [41–44], was
not able to demonstrate a disease-causing effect leaving genotype–phenotype correlation for NR5A1
variants unsolved. Many patients with variants in NR5A1 have been described with broad phenotypes
ranging from severe 46,XY DSD to unvirilized males with/without adrenal failure, 46,XX with ovarian
insufficiency, 46,XX with ovotesticular DSD, and healthy carriers [45]. On the other hand, it has also
been shown that SF-1 has an extraordinary network of regulators, modulators, and target genes [46–48].
We therefore performed a WES analysis in four of these 46,XY DSD patients with heterozygous
NR5A1 gene defects [13] in search for additional genetic hits explaining the phenotypic variability
described in patients with NR5A1 mutations [45]. For specific bioinformatic analysis, candidate genes
for DSD and genes related to NR5A1 were collected from the literature and databases including
known and potential candidate genes. Included DSD-related genes were associated to DSD conditions
in humans or rodent models or related to gonadal or sex development; and SF-1/NR5A1-related
genes were associated to SF-1 regulation or modulation. An algorithm for data analysis based on
these selected project-specific DSD- and SF-1/NR5A1-related genes led us to identify 19 potentially
deleterious variants, one to seven per patient in 18 genes (e.g., AKR1C2, CACNG4, CHD7, DENND1A,
DOCK8, FBLN2, FOG2/ZFPM2, FSHR, GDNF, GLI2, INHA, NAV1, NCOR1, POR, SMAD6, SOX30,
SRA1, and ZDHHC11) [13]. Eight of these genes had been previously reported as DSD-causing in
humans. Variants related to 46,XY DSD/CHH were found in genes CHD7, FOG2/ZFPM2, and SRA1,
variants related to 46,XX DSD/CHH/primary ovarian insufficiency were found in CHD7, DENND1A,
FSHR, GLI2, INHA, POR, and SRA1. Other identified gene variants (n = 7) in AKR1C3, DOCK8, NCOR1,
FBLN2, NAV1, SMAD6, and GDNF were not previously related to sex development or gonadal function.
By contrast, we also observed variants in genes CACNG4, ZDHHC11, and SOX30 that have been
previously discussed as strong DSD candidates [46,49]. With respect to gene interactions with SF-1,
nine of the detected genes have been previously shown to interact with SF-1/NR5A1 in functional
studies [46–48,50,51]: five of them (FSHR, CACNG4, GLI2, SMAD6, and ZDHHC11) as targets of
SF-1 [46–48], another three (NCOR1, SOX30 and SRA1) as regulators of SF-1 [47,50], and INHA as both
SF-1 target and regulator [47]. From these data, we were able to construct a scheme of all hits within the
landscape of currently known genes involved in male sex determination and differentiation (Figure 1).
The results suggested that the broad phenotypes in heterozygous NR5A1 46,XY DSD subjects may be
explained by an oligogenic mechanism, in which multiple hits may contribute to a DSD phenotype
unique to each heterozygous SF-1/NR5A1 individual [13] (Figure 1).
More recently, we performed a WES study in eight DSD patients (seven 46,XY and one 46,XX)
carrying sequence variation in MAMLD1 previously detected by Sanger sequencing [6]. Seven of eight
MAMLD1 sequence variations did not show alterations in functional activity in vitro when compared
to wild-type MAMLD1 and thus did not explain the DSD phenotype sufficiently [40]. So far, the
role of MAMLD1 in sex development is controversial for several reasons, including that the same
MAMLD1 variant may be present in healthy carriers and in 46,XY DSD patients with different severity
of phenotypes [40]. We, therefore, hypothesized that MAMLD1 variants may also not suffice to explain
the 46,XY DSD phenotype. WES data from these patients were obtained and filtered by an algorithm
including disease-tailored lists of MAMLD1-related and DSD-related genes [6]. This analysis showed
that patients harbored 1–16 variants in 1–16 genes together with their MAMLD1 variation. Fifty-five
potentially deleterious variants in 41 genes were identified. Seventeen variants were reported in
genes that had been previously associated with hypospadias (ATF3, BNC2, CYP1A1, EMX2, EYA1,
FLNA, GLI3, GRID1, GLI2, BNC2, FGF10, HOXA13, HSD3B2, IRX5, IRX6, PPARGC1B, and WDR11),
eight with cryptorchidism (BNC2, FLNA, RET, RECQL4, NRP1, PTPN11, RIPK4, and ZBTB16), and
five with micropenis (ZBTB16, BNC2, EVC, FGF10, and RIPK4). Moreover, 16 identified genes had
been previously described in other types of DSD (CUL4B, EMX2, FRAS1, FREM2, HSD3B2, NOTCH2,
and NRP1) and/or were reported in different syndromes (CYP1A1, EVC, FRAS1, HOXA13, PTPN11,
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RECQL4, RET, RIPK4, and ZBTB16). In addition, 27 genes had been previously described in the
context of sex or gonadal development (ATF3, BNC2, CDH23, COL9A3, DAPK1, EMX2, EVC, EYA1,
FLNA, FRAS1, FREM2, GLI2, GLI3, HOXA13, IGFBP2, IRX5, MAML3, MYO7A, NOTCH1, NOTCH2,
NRP1, PIK3R3, RET, RIPK4, TGFBI, WNT9A, and WNT9B). By contrast, only 13 genes (ATF3, DAPK1,
EMX2, FLNA, FRAS1, FREM2, GLI3, IGFBP2, IRX5, MAML3, PIK3R3, WNT9A, and WNT9B) had been
previously described in female gonadal development and 46,XX DSD and eight of them (DAPK1,
EMX2, FREM2, IGFBP2, MAML3, PIK3R3, WNT9A, and WNT9B) were found in the 46,XX DSD patient
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Nineteen of the 41 genes had been previously published in DSD panels (ATF3, BNC2, CUL4B,
EVC, FLNA, FRAS1, FREM2, GLI3, HOXA13, HSD3B2, IRX5, NOTCH2, PROP1, PTPN11, RECQL4,
RET, RIPK4, WDR11, ZBTB16). In addition, with this study we are adding 22 new candidate genes to
the list of genes to consider in DSD (CDH23, COL9A3, CYP1A1, DAPK1, EMX2, EYA1, FGF10, GLI2,
GRID1, IGFBP2, IRX6, MAML1, MAML2, MAML3, MYO7A, NOTCH1, NRP1, PIK3R3, PPARGC1B,
TGFBI, WNT9A, and WNT9B).
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A search for an underlying network comprising variants in the identified genes related to MAMLD1
revealed a considerable number of genes (n = 23) that showed interactions suggesting that genetic
variations in these genes may affect sex development in concert. Interestingly, MAML3 (one variant in
our 46,XX DSD patient) was found in a network related to female gonadal development [52]. Overall,
three genes seemed prominent in the network analysis: NOTCH1/NOTCH2 and GLI3 (Figure 2) [6].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 15 
 
ZBTB16), and five with micropenis (ZBTB16, BNC2, EVC, FGF10, and RIPK4). Moreover, 16 identified 
genes had been previously described in other types of DSD (CUL4B, EMX2, FRAS1, FREM2, HSD3B2, 
NOTCH2, and NRP1) and/or were reported in different syndromes (CYP1A1, EVC, FRAS1, HOXA13, 
PTPN11, RECQL4, RET, RIPK4, and ZBTB16). In addition, 27 genes had been previously described in 
the context of sex or gonadal development (ATF3, BNC2, CDH23, COL9A3, DAPK1, EMX2, EVC, 
EYA1, FLNA, FRAS1, FREM2, GLI2, GLI3, HOXA13, IGFBP2, IRX5, MAML3, MYO7A, NOTCH1, 
NOTCH2, NRP1, PIK3R3, RET, RIPK4, TGFBI, WNT9A, and WNT9B). By contrast, only 13 genes 
(ATF3, DAPK1, EMX2, FLNA, FRAS1, FREM2, GLI3, IGFBP2, IRX5, MAML3, PIK3R3, WNT9A, and 
WNT9B) had been previously described in female gonadal development and 46,XX DSD and eight of 
them (DAPK1, EMX2, FREM2, IGFBP2, MAML3, PIK3R3, WNT9A, and WNT9B) were found in the 
46,XX DSD patient (Table 1). 
Nineteen of the 41 genes had been previously published in DSD panels (ATF3, BNC2, CUL4B, 
EVC, FLNA, FRAS1, FREM2, GLI3, HOXA13, HSD3B2, IRX5, NOTCH2, PROP1, PTPN11, RECQL4, 
RET, RIPK4, WDR11, ZBTB16). In addition, with this study we are adding 22 new candidate genes to 
the list of genes to consider in DSD (CDH23, COL9A3, CYP1A1, DAPK1, EMX2, EYA1, FGF10, GLI2, 
GRID1, IGFBP2, IRX6, MAML1, MAML2, MAML3, MYO7A, NOTCH1, NRP1, PIK3R3, PPARGC1B, 
TGFBI, WNT9A, and WNT9B). 
A search for an underlying network comprising variants in the identified genes related to 
MAMLD1 revealed a considerable number of genes (n = 23) hat s owed int raction  sugg sting that 
genetic variations in these genes may affect sex development in concert. Interestin ly, MAML3 (on  
variant in our 46,XX DSD patient) was found in a network related to female gonadal development 
[52]. Overall, three genes seemed prominent in the network analysis: NOTCH1/NOTCH2 and GLI3 
(Figure 2) [6]. 
 
Figure 2. Interaction network of DSD- and MAMLD1-related genes identified in DSD individuals 
harboring genetic variants in MAMLD1. The scheme depicts an overview of detected genes and their 
interrelationship. For the search for functional human partners, we used the Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING, http://string-db.org/). Nodes represent proteins. 
Filled nodes show proteins with known or predicted 3D structure. Empty nodes depict proteins with 
Figure 2. Interaction network of DSD- and MAMLD1-related genes identified in DSD individuals
harboring genetic variants in MAMLD1. The scheme depicts an overview of detected genes and their
interrelationship. For the search for functional human partners, we used the Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING, http://string-db.org/). Nodes represent proteins. Filled nodes
show proteins with known or predicted 3D structure. Empty nodes depict proteins with unknown
3D structure. Candidate genes are underlined. Known interactions correspond to curated databases
(turquoise lines) and experimentally determined interactions (pink lines). Predicted interactions
correspond to gene neighborhood (green lines), gene fusions (red lines), and gene co-occurrence (blue
lines). Other interactions correspond to text mining (yellow lines), co-expression (black lines), and
protein homology (violet lines). Reproduced from [6].
To summarize, results from the above studies have identified a digenic or oligogenic disorder
in DSD mainly by combining mutations in genes involved more frequently in gonadal development
(NR5A1, MAP3K1, ZFPM2, GATA4, CHD7, HOXA13, and MAMLD1 combined with other gonadal
development genes), followed by the AR gene combined with gonadal development genes and less
frequently with steroidogenesis genes.
5. Perspectives and Pitfalls
With the rapid evolution of HTS technology in terms of improving quality and diminishing costs,
it is now conceivable that the best recommendable genetic diagnostic approach in 46,XY DSD patients
and 46,XX DSD non-CAH patients is using a HTS technology [3]. In this perspective, although panels
of candidate genes offer guaranteed coverage, candidate gene lists are growing fast and harnessing
gene panels (even economically) is getting more and more difficult. Consequently, whereas gene
panels become regularly outdated, WES allows the analysis of as many genes as wanted and affording
re-analyses at any demand.
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On the other hand, identification of “large” CNVs has been historically restricted to other
(molecular) techniques such as array-CGH. This is also being solved nowadays in gene panels, as their
robust coverage allows the detection of large deletions and duplications thanks to newly developed
bioinformatic tools such as ExomeDepth [53]. Furthermore, some studies demonstrate that this analysis
is already possible for WES, yet it needs some improvement [54].
Nevertheless, with the identification of more variants it becomes even more difficult to distinguish
between what is contributing to the phenotype and what is not. This leads to discuss the difficulties of
studying polygenic disorders. In this perspective, polygenic outcome has to face the following points:
(a) Algorithms of analysis including gene lists may enrich potentially deleterious variants that
may ultimately not affect sex development, yet makes the analysis easier as the gene lists can be
regularly updated. On the other hand, another possibility of analysis could be a “blind” analysis
following the filtering criteria, yet without filtering by the gene lists. This would give the whole picture,
but many other potentially affected genes indeed without any relationship with sex development or
gonadal function may arise, making the outcome harder to understand. Maybe these two approaches
could be done in parallel, to have a whole picture of the patient, mainly when the gene-list approach is
not giving a “clue”.
(b) Bioinformatic network analysis can help in interpreting complex genetic data and put identified
single candidate genes into a greater perspective to understand their possible role in DSD biology.
There are some tools, such as STRING (https://string-db.org/), BioGRID (https://thebiogrid.org/), and
databases that can help, yet we have to be cautious when using these networks, as they need expert
eyes to interpret them.
(c) Biostatistics requires large sample sizes mostly not available in rare disorders such as DSD.
Related to this, we would like to emphasize the need for multidisciplinary teams of medical specialists
and researchers to implement multicenter collaborations by using well-accredited international
registries such as the I-DSD Registry [55] and the European Reference Network for Rare Endocrine
Diseases (EndoERN) [56].
(d) Cell and animal models used in monogenic diseases are useful until a certain point: it is still
feasible to study some gene variants and a discreet number of genes at the same time in the same
model, but not in the case of “many” variants. Due to the complexity of sex development itself, a
proper cell model has been searched for, for many years, to properly mimic patients’ phenotypes and
study DSD-related candidate genes and role of candidate variants. Nowadays, new techniques based
on cell reprograming and in vitro guided differentiation (from differentiated cells to pluripotent stem
cells to redifferentiated cells again) open the field to adequate models for DSD in the near future to
predict the role of candidate variants [57–59].
In summary, recent studies support the concept that the broad range of some DSD phenotypes may
be due to digenic or oligogenic origin similarly to results described in other endocrine disorders such
as CHH and congenital hypothyroidism. This is conceivable as sex developmental biology is complex
and involves a vast network of genes. While some DSD phenotypes can be explained sufficiently by
monogenetic defects, others may be caused by multiple minor hits in genetic networks. Whether these
genes form clusters remains unknown until results of bigger cohorts of DSD individuals are studied.
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